November 22, 2016 - By Ellis Scott · 0 Comments
Novogen LTD (NASDAQ:NVGN) institutional sentiment increased to 3 in 2016 Q2. Its up 2.67, from 0.33 in 2016Q1. The ratio has improved, as 1 investment managers started new or increased stock positions, while 3 reduced and sold stakes in Novogen LTD. The investment managers in our partner’s database now possess: 255,652 shares, up from 233,741 shares in 2016Q1. Also, the number of investment managers holding Novogen LTD in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 1 Increased: 1 New Position: 0.
Novogen Limited is an oncology biotechnology company, which is focused on developing cancer treatments. The company has a market cap of $31.70 million. The Firm is primarily engaged in pharmaceutical research and development. It currently has negative earnings. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.
The stock increased 0.59% or $0.01 on November 21, hitting $1.69. Novogen Limited (ADR) (NASDAQ:NVGN) has declined 32.94% since April 20, 2016 and is downtrending. It has underperformed by 37.49% the S&P500.
According to Zacks Investment Research, “NOVOGEN LTD-ADR business is in the area of medicine know as degenerative diseases and disorders. Novogen is addressing this urgent area of medical need through the Novogen isoflavonoid technology platform – a platform that the Company believes offers the real prospect of not only treating, but also preventing, the onset of these common degenerative conditions. There are three divisions at Novagen: the pharmaceutical division, Marshall Edwards inc., and the consumer health division.”
Bank Of America Corp De holds 0% of its portfolio in Novogen Limited (ADR) for 89,042 shares. Creative Planning owns 400 shares or 0% of their US portfolio. Moreover, Deutsche Bank Ag has 0% invested in the company for 92 shares. The New York-based Morgan Stanley has invested 0% in the stock. Renaissance Technologies Llc, a New York-based fund reported 137,300 shares.#img1#
Novogen Limited (Novogen), incorporated on March 18, 1994, is an oncology biotechnology company, which is focused on developing cancer treatments. The Firm is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company’s product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company’s target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma.
More notable recent Novogen Limited (ADR) (NASDAQ:NVGN) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on February 13, 2011, also Benzinga.com with their article: “Must Watch Stocks for September 12, 2016” published on September 12, 2016, Fool.com.Au published: “Novogen Limited sinks 30%: Here’s why” on April 21, 2015. More interesting news about Novogen Limited (ADR) (NASDAQ:NVGN) were released by: Bidnessetc.com and their article: “Pharma Stocks To Watch: Novogen Ltd. (NVGN), Auspex Pharmaceuticals (ASPX …” published on December 17, 2014 as well as Benzinga.com‘s news article titled: “Must Watch Stocks for October 31, 2016” with publication date: October 31, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott